Overcoming upstream and downstream process barriers for large-scale AAV production
Given the broad treatment potential and demonstrated efficacy of recently approved viral vector-based gene therapies, there is an established need for reproducible and consistent manufacturing solutions that yield high titer, high quality viral particles for clinical applications. Download now to learn about key barriers to addressing clinical needs and market supply of gene therapies, and […]
Overcoming upstream and downstream process barriers for large-scale AAV production Read More »










